PCI Pharma Services is investing more than $20m to expanded Biotech clinical and commercial packaging and release testing capabilities at its centre of excellence in Philadelphia, US.

The move will support its biologic medicines and advanced injectable delivery forms.

PCI will use the investment to expand the labelling and assembly of safety syringes, autoinjector and pen devices with integrated high-speed cartoning, in-line serialisation, as well as its onsite cold chain storage.

PCI CEO Salim Haffar said: “I am pleased to share this news regarding our continued investment to support the needs of our biotech customers.

“We are proud to be the partner of choice for drug development companies as they look to outsource these specialised requirements for clinical and commercial packaging.

“These investments demonstrate our commitment to bringing lifesaving medicines to patients around the world.”

PCI offers clinical and commercial packaging services of various delivery forms such as injectables, topicals, transdermals and solid oral dose.

“These investments demonstrate our commitment to bringing lifesaving medicines to patients around the world.”

The company’s injectable delivery form capabilities include ampoules, vials, cartridges and standard prefilled syringes, advanced safety syringes, autoinjectors and pen devices.

It currently operates facilities in the US, the UK, Europe, and Australia, to serve its customers across more than 100 countries globally.

In October, PCI completed the acquisition of Sherpa Clinical Packaging in a move to expand its clinical services network to California, US.

The acquisition represents complementary packaging, labelling, distribution, temperature-controlled storage and returns services.